

# Alessandra Decio

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3279266/publications.pdf>

Version: 2024-02-01

22  
papers

855  
citations

567144

15  
h-index

713332

21  
g-index

25  
all docs

25  
docs citations

25  
times ranked

1886  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cannabidiol reduced the striatal atrophy caused by nitropropionic acid <i>in vivo</i> by mechanisms independent of the activation of cannabinoid, vanilloid TRPV <sub>1</sub> and adenosine A <sub>2A</sub> receptors. <i>European Journal of Neuroscience</i> , 2007, 26, 843-851.	1.2	120
2	Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic Alterations. <i>Cancer Research</i> , 2014, 74, 6980-6990.	0.4	110
3	Angiotensin-(1-7) improves oxygenation, while reducing cellular infiltrate and fibrosis in experimental Acute Respiratory Distress Syndrome. <i>Intensive Care Medicine Experimental</i> , 2015, 3, 44.	0.9	81
4	Cannabinoids and Neuroprotection in Basal Ganglia Disorders. <i>Molecular Neurobiology</i> , 2007, 36, 82-91.	1.9	79
5	Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging. <i>Scientific Reports</i> , 2016, 6, 39284.	1.6	68
6	The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling. <i>EMBO Molecular Medicine</i> , 2011, 3, 480-494.	3.3	67
7	Vascular Endothelial Growth Factor C Promotes Ovarian Carcinoma Progression through Paracrine and Autocrine Mechanisms. <i>American Journal of Pathology</i> , 2014, 184, 1050-1061.	1.9	56
8	Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 125-135.	1.9	56
9	The ER stress response mediator ERO1 triggers cancer metastasis by favoring the angiogenic switch in hypoxic conditions. <i>Oncogene</i> , 2021, 40, 1721-1736.	2.6	31
10	Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models. <i>British Journal of Cancer</i> , 2012, 107, 360-369.	2.9	29
11	Syngeneic Murine Metastasis Models: B16 Melanoma. <i>Methods in Molecular Biology</i> , 2014, 1070, 131-140.	0.4	29
12	Chemotherapy Counteracts Metastatic Dissemination Induced by Antiangiogenic Treatment in Mice. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2237-2247.	1.9	23
13	Contribution of tumor endothelial cells to drug resistance: anti-angiogenic tyrosine kinase inhibitors act as p-glycoprotein antagonists. <i>Angiogenesis</i> , 2017, 20, 233-241.	3.7	22
14	L1CAM promotes ovarian cancer stemness and tumor initiation via FGFR1/SRC/STAT3 signaling. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 319.	3.5	20
15	Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 647-658.	1.7	17
16	PGC1 $\alpha$ Expression Predicts Therapeutic Response to Oxidative Phosphorylation Inhibition in Ovarian Cancer. <i>Cancer Research</i> , 2022, 82, 1423-1434.	0.4	14
17	Impact of ERCC1, XPF and DNA Polymerase $\beta$ Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts. <i>Cancers</i> , 2020, 12, 2398.	1.7	9
18	Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab. <i>International Journal of Cancer</i> , 2018, 143, 2187-2199.	2.3	8

#	ARTICLE	IF	CITATIONS
19	Past-in-the-Future. Peak detection improves targeted mass spectrometry imaging. <i>Analytica Chimica Acta</i> , 2018, 1042, 1-10.	2.6	7
20	Orthotopic Model of Ovarian Cancer. <i>Methods in Molecular Biology</i> , 2016, 1464, 139-149.	0.4	7
21	Abstract 2816: Patient derived ovarian cancer xenograft (OC-PDX) to study the response of the PARP inhibitor olaparib. , 2018, , .		1
22	Abstract 2406: Metabolic phenotype and metastasis in patient-derived ovarian cancer xenografts. , 2018, , .		0